Wang Z, Whipp AM, Heinonen-Guzejev M, Foraster M, Julvez J, Kaprio J. The association between urban land use and depressive symptoms in young adulthood: a FinnTwin12 cohort study. J Expo Sci Environ Epidemiol. 2023 Dec 11. doi: 10.1038/s41370-023-00619-w
John NM, Wright SJ, Gavan SP, Vass CM. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. Eur J Health Econ. 2019 Nov;20(8):1123-31. doi: 10.1007/s10198-019-01082-x
Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar;19(2):229-40. doi: 10.1007/s10198-017-0879-5.
Danysh HE, Mitchell LE, Zhang K, Scheurer ME, Lupo PJ. Differences in environmental exposure assignment due to residential mobility among children with a central nervous system tumor: Texas, 1995-2009. J Expo Sci Environ Epidemiol. 2017 Jan;27(1):41-6. doi: 10.1038/jes.2015.63
Cole-Hunter T, Weichenthal S, Kubesch N, Foraster M, Carrasco-Turigas G, Bouso L, Martinez D, Westerdahl D, de Nazelle A, Nieuwenhuijsen M. Impact of traffic-related air pollution on acute changes in cardiac autonomic modulation during rest and physical activity: a cross-over study. J Expo Sci Environ Epidemiol. 2016 Mar;26(2):133-40. doi: 10.1038/jes.2015.66
Hansen MK, Gammelager H, Jacobsen CJ, Hjortdal VE, Layton JB, Rasmussen BS, Andreasen JJ, Johnsen SP, Christiansen CF. Acute kidney injury and long-term risk of cardiovascular events after cardiac surgery: a population-based cohort study. J Cardiothorac Vasc Anesth. 2015 Jun;29(3):617-25. doi: 10.1053/j.jvca.2014.08.020
Aguilera I, Foraster M, Basagana X, Corradi E, Deltell A, Morelli X, Phuleria HC, Ragettli MS, Rivera M, Thomasson A, Slama R, Kunzli N. Application of land use regression modelling to assess the spatial distribution of road traffic noise in three European cities. J Expo Sci Environ Epidemiol. 2015 Jan;25(1):97-105. doi: 10.1038/jes.2014.61
Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013 May;Advance online publication.
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Lehmann K, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Duragesic) with controlled release morphine. Eur J Health Econ. 2002;3:111-9. doi: 10.1007/s10198-002-0097-6.